Heartflow, Inc. (NASDAQ:HTFL) Receives $36.60 Average PT from Brokerages

Shares of Heartflow, Inc. (NASDAQ:HTFL) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $36.60.

Several equities research analysts have recently commented on HTFL shares. Morgan Stanley started coverage on Heartflow in a report on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 target price for the company. Piper Sandler started coverage on Heartflow in a report on Tuesday, September 2nd. They set an “overweight” rating and a $38.00 target price for the company. Canaccord Genuity Group upped their target price on Heartflow from $35.00 to $39.00 and gave the company a “buy” rating in a report on Monday, September 22nd. Stifel Nicolaus began coverage on Heartflow in a report on Tuesday, September 2nd. They set a “buy” rating and a $35.00 target price for the company. Finally, Wall Street Zen raised Heartflow to a “hold” rating in a research note on Saturday, August 16th.

Heartflow Trading Up 4.0%

Shares of Heartflow stock opened at $37.64 on Friday. Heartflow has a fifty-two week low of $26.56 and a fifty-two week high of $38.52.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings data on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The firm had revenue of $43.42 million during the quarter, compared to analyst estimates of $43.20 million.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.